News & Updates

High-intensity training eases anxiety, stress in prostate cancer
High-intensity training eases anxiety, stress in prostate cancer
17 Apr 2022

A supervised high-intensity interval training (HIIT) program for 12 weeks leads to improvements in prostate cancer-specific anxiety, fear of cancer progression, hormone symptoms, stress, fatigue, and self-esteem in men on active surveillance, reports a study.

High-intensity training eases anxiety, stress in prostate cancer
17 Apr 2022
Erectile dysfunction common among men with anxiety
Erectile dysfunction common among men with anxiety
11 Apr 2022

Men with anxiety disorder commonly suffer from concomitant erectile dysfunction, according to a recent systematic review.

Erectile dysfunction common among men with anxiety
11 Apr 2022
Delaying reproductive surgeries due to pandemic severely compromises personal life
Delaying reproductive surgeries due to pandemic severely compromises personal life
09 Apr 2022

The coronavirus disease 2019 (COVID-19) pandemic has caused the postponement of several sexual and reproductive health surgeries, which in turn leads to severe restrictions in the patients’ private lives and aggravates their worries about their disease, a recent study has found.

Delaying reproductive surgeries due to pandemic severely compromises personal life
09 Apr 2022
Google Trends hint at erectile dysfunction being more common during winter
Google Trends hint at erectile dysfunction being more common during winter
08 Apr 2022

Between 2009 and 2019, Google searches regarding erectile dysfunction (ED) across the United States peak during winter, hinting at a potential seasonal dimension of ED, a recent study has found.

Google Trends hint at erectile dysfunction being more common during winter
08 Apr 2022
ED patients who do not respond to PDE5I may benefit from topical alprostadil–PDE5i combo
ED patients who do not respond to PDE5I may benefit from topical alprostadil–PDE5i combo
04 Apr 2022 byJairia Dela Cruz

For men with erectile dysfunction (ED) who show a lack of response to oral phosphodiesterase type 5 inhibitors (PDE5Is), combination therapy with topical alprostadil plus PDE5Is seems favourable, producing greater improvements in sexual function without compromising safety compared with topical alprostadil alone, as shown in a study.

ED patients who do not respond to PDE5I may benefit from topical alprostadil–PDE5i combo
04 Apr 2022